Athebody® DARPins for Targeted AAV/LNP Delivery

About Athebio

Athebio is a privately held biotech company founded in 2019, leveraging its Athebody® DARPin platform to empower drug developers with a versatile, 'plug & play' scaffold for creating superior targeted therapeutics. The company's mission is to explore and unleash the therapeutic potential of repeat proteins, offering partners a technology characterized by high specificity, solubility, stability, and ease of manufacturing. Athebio's business model is centered on strategic partnerships and technology transfer, as evidenced by its collaboration with POINT Biopharma to develop targeted radioligands.

Therapeutic Areas